ANI Pharmaceuticals ANIP Rare Disease total net revenues — Net Revenues

Similar metrics at other companies

BIIBRare Disease Product Revenue — Total Revenue

$557.2M-1.1%

HRMYRare Neurological Diseases — Revenue

$215.39M+16.6%

BMRNNet product revenues — Total revenues

$760.08M+3.5%

RYTMProduct revenue, net — Total revenues

$60.11M+59.4%

BBIONet product revenue — Revenue

$180.6M+392%

EXELNet product revenues — Total revenues

$554.98M+8.1%

Questions, answered.

What is ANI Pharmaceuticals's rare disease total net revenues — net revenues?

ANI Pharmaceuticals (ANIP) reported rare disease total net revenues — net revenues of $94.37M in Q1 2026.

How has ANI Pharmaceuticals's rare disease total net revenues — net revenues changed year-over-year?

ANI Pharmaceuticals's rare disease total net revenues — net revenues increased by 36.9% year-over-year, from $68.96M to $94.37M.

What is the long-term trend for ANI Pharmaceuticals's rare disease total net revenues — net revenues?

Over 2 years (2022 to 2025), ANI Pharmaceuticals's rare disease total net revenues — net revenues has grown at a 218.4% compound annual growth rate (CAGR), from $41.69M to $422.65M.

What does rare disease total net revenues — net revenues mean?

This metric represents the total gross sales of pharmaceutical products specifically indicated for rare diseases, adjusted for returns, rebates, and other revenue deductions. It serves as a key indicator of the company's success in commercializing specialized therapeutic assets and capturing market share within the orphan drug sector. Growth in this segment reflects the company's strategic focus on high-value, complex formulations and the successful expansion of its rare disease portfolio.